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Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver 
disease and is one of the most common liver diseases in the developed world.  The 
histological findings of NASH are characterized by hepatic steatosis, inflammation, and 
fibrosis.  To date, however, the optimal treatment of NASH has not been established.  
Tranilast, N-(3′,4′-dimethoxycinnamoyl)-anthranilic acid, is an anti-fibrogenic agent 
that inhibits the action of transforming growth factor (TGF)-β.  This drug is used 
clinically for fibrogenesis-associated skin disorders including hypertrophic scars and 
scleroderma.  TGF-β plays a central role in the development of hepatic fibrosis, and 
tranilast may thus ameliorate the pathogenesis of NASH.  We investigated the effects 
of tranilast by using an established dietary animal model of NASH, obese diabetic 
Otsuka Long–Evans Tokushima Fatty (OLETF) rats and nondiabetic control 
Long–Evans Tokushima Otsuka (LETO) rats fed a methionine- and choline-deficient 
diet.  Treatment with 2% tranilast (420 mg kg day ) –1 –1 for 8 weeks prevented the 
development of hepatic fibrosis and the activation of stellate cells, and down-regulated 
expression of genes for TGF-β and TGF-β-target molecules, including α1 procollagen 
and plasminogen activator-1.  In addition, tranilast attenuated hepatic inflammation 
and Kupffer cells recruitment, and down-regulated expression of tumor necrosis 
factor-α (TNF-α).  Unexpectedly, tranilast ameliorated hepatic steatosis, and 
up-regulated expression of genes involved in β-oxidation, such as peroxisome 
proliferator-activated receptor α and carnitine O-palmitoyltransferase-1.  Most of these 
effects were observed in LETO rats and OLETF rats, which suggest that the action of 
tranilast is mediated through the insulin resistance-independent pathway.  Further, 
TNF-α and interleukin-6 (IL-6) expression in RAW 264.7 macrophages was suppressed 
by tranilast.  Conclusion: Our findings suggest that targeting TGF-β with tranilast 
represents a new mode of therapy for NASH.   
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Introduction 
   Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases 
in the United States and other developed countries1, 2 and involves a wide spectrum of 
liver disease, ranging from simple steatosis to steatohepatitis and cirrhosis. 
Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, is characterized 
by steatosis, inflammation, and fibrosis.  It has recently been proposed that NAFLD be 
included as a component of the metabolic syndrome, a cluster of metabolic 
abnormalities with visceral fat accumulation, hyperglycemia, hypertension, and 
dyslipidemia.3–5  Insulin resistance, an underlying factor in these metabolic disorders, 
may play a critical role in the pathogenesis of NASH.  We recently created a rat model 
of NASH with insulin resistance, abundant visceral fat tissue, hyperglycemia, and 
hypertension, and demonstrated that pioglitazone, a peroxisomal proliferator-activated 
receptor (PPAR)-γ agonist, prevents the progression of NASH, mainly through 
enhancement of insulin resistance.6 However, it has remained unresolved whether all 
patients with NASH respond to insulin-sensitizing agents such as PPARγ agonists,7 and 
the optimal treatment of NASH has not been established.   
   Transforming growth factor (TGF)-β is a multifunctional peptide that play a pivotal 
role in fibrogenesis.8–11  High levels of TGF-β are often found in hepatic fibrosis and it 
has been implicated as a mediator of fibrosis in several liver diseases.12  TGF-β 
stimulates collagen synthesis in cultured stellate cells, and hepatic overexpression of 
TGF-β in transgenic mice has been shown to cause hepatic fibrosis.13, 14  Several lines 
of evidence have demonstrated that the blockade of TGF-β synthesis or signaling using 
different experimental strategies prevents liver fibrosis in various animal models.15–18  
TGF-β is also known to play a central role in the development of NASH by activating 
hepatic fibrosis.19  Thus, TGF-β signaling can be designated as a potential 
anti-fibrogenic target for the treatment of fibrosis-associated liver diseases.   
   Tranilast, N-(3′,4′-dimethoxycinnamoyl)-anthranilic acid, was originally developed 
as an antiallergic drug for the systemic and topical treatment of bronchial asthma, atopic 
dermatitis, and allergic conjunctivitis because it inhibits the release of chemical 
mediators from mast cells and cytokines from macrophages.8 More recently, tranilast 
has been reported to exert anti-fibrogenic effects by inhibiting the action of TGF-β.  In 
fact, tranilast has been used clinically for the treatment of hypertrophic scars, 
scleroderma, and skin disorders associated with an excessive fibrogenic response.20, 21  
We previously found that tranilast prevents renal fibrosis in animal models of diabetic 
nephropathy, through the suppression of TGF-β.22  To date, however, no reports are 
available on the effect of tranilast in animal models of liver diseases.   
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   We therefore hypothesized that administration of tranilast would exert a beneficial 
effect on the pathology of NASH by suppressing TGF-β activity and development of 
hepatic fibrosis. To test this hypothesis, we investigated the effect of tranilast by using 




   Animal model and experimental design. Male Otsuka Long–Evans Tokushima 
Fatty (OLETF) rats, an established animal model of obese type 2 diabetes,23 were used 
(Otsuka Pharmaceutical, Tokushima, Japan).  Spontaneous-onset type 2 diabetic 
OLETF rats showed obesity and hyperinsulinemia from 8 weeks of age.  NAFLD has 
been studied in OLETF rats because these animals show an age-dependent increase of 
fat accumulation in the liver. All rats in the OLETF group developed diabetes after 24 
weeks of age (data not shown) as described previously.23, 24  As control animals, 
4-week-old OLETF and Long–Evans Tokushima Otsuka (LETO) rats, which originated 
from the same colony as the OLETF rats by selective mating but do not develop 
diabetes, were obtained and housed in a room under controlled temperature (25°C), 
humidity, and lighting (12-h artificial light and dark cycle).  Animals were given free 
access to standard laboratory rat chow and tap water. At 24 weeks of age, OLETF rats 
were divided into two experimental groups and fed for 8 weeks as follows: MCD diet 
(Oriental Yeast, Tokyo, Japan; OLETF-MCD, 21% fat, n = 11), and MCD-tranilast diet 
(OLETF-MCD-trani; tranilast content 1%, n = 3,1.4%, n = 3, 2%, n = 10).  In addition, 
at 24 weeks of age, male LETO rats were divided into two groups: MCD diet 
(LETO-MCD, n = 9) and MCD-tranilast diet (LETO-MCD-trani; tranilast content 2%, n 
= 5). The rats were allowed unrestricted access to water and the standard or mixed chow. 
The weight and food intake in each group of rats were recorded every week.  Tranilast 
was donated by Kissei Pharmaceutical Co. (Nagano, Japan). All animal procedures were 
performed in accordance with the standards set forth in the Guidelines for the Care and 
Use of Laboratory Animals at the Takara-machi campus of Kanazawa University.  
 
   Blood sampling and analysis. After 8 weeks, the rats were killed, and blood 
samples were obtained from the heart after a 12-h fast.  Blood glucose was determined 
by the Freestyle Kissei monitor (Kissei pharmaceutical, Matsumoto, Japan).  The 
blood samples were centrifuged, and serum was frozen at –70°C for subsequent 
measurement of serum alanine aminotransferase (ALT), triglyceride, free fatty acid 
(FFA), total cholesterol (TC), and HDL-cholesterol (HDL-C) levels. Plasma ALT was 
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determined by spectrophotometry (Sigma, St. Louis, MO, USA), according to the 
manufacturer’s instructions.  Plasma FFA levels were determined by a non-esterified 
fatty acid (NEFA) C-test (Wako, Osaka, Japan). TC and HDL-C concentrations were 
quantified by colorimetry, as described previously.21  Plasma levels of insulin and 
tumor necrosis factor-α (TNF-α) were determined by ELISA (Mercodia, Uppsala, 
Sweden) (Bender Medsystems, Vienna, Austria). 
 
   Measurement of serum glucose levels. Before 3 days of sacrifice, all rats underwent 
an oral glucose tolerance test after a 12-h fast.  Glucose (2 g kg−1) was administered 
orally. Blood was drawn from a tail vein at 0, 60, and 120 min for measurement of 
serum glucose concentrations.  
 
   Measurement of serum and liver triglyceride levels. After 8 weeks, the rats were 
killed, and liver weight and triglyceride level were measured.  For quantification of the 
hepatic triglyceride content, the liver was lysed with the buffer in a commercially 
available kit (TG E-test; Wako).   
 
   Morphological analysis and immunohistochemistry. After 8 weeks on each diet, 
the animals were killed and their livers were fixed in 10% buffered formalin and 
embedded in paraffin. Severity of hepatic histological changes were assessed by 
hematoxylin and eosin (H&E) and Azan staining, and blindly scored by a single 
pathologist. Steatosis, fibrosis, and disease activity were semiquantitatively evaluated 
according to the standard criteria of grading and staging for NASH, with minor 
modifications.25  Degree of steatosis was scored as the percentage of hepatocytes 
containing lipid droplets. Fibrosis scores were as follows: 1, pericellular and perivenular 
fibrosis; 2, focal bridging fibrosis; 3, bridging fibrosis with lobular distortion; and 4, 
cirrhosis. Disease activity was evaluated as the sum of scores (score 0–6) of acinar 
inflammation (score 0–3) and portal inflammation (score 0–3).  
Slides were immunostained with monoclonal mouse antihuman α-smooth muscle 
actin (α-SMA) (Dako, Kyoto, Japan) and anti-rabbit TGF-β (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) and ED1 (AbD, SerotecOxford, UK). This was followed by 
application of the immunoperoxidase technique using an Envision kit (Dako). 
Peroxidase activity was identified by reaction with 3',3'-diaminobenzidine (Sigma). 
Two independent observers with no previous knowledge of the experimental design 
evaluated each section. Positive staining with anti-α-SMA or anti-TGF-β or ED1 was 
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expressed as a percentage of the field, using WinROOF version 5.71 (Mitani Shoji, 
Fukui, Japan).  
 
   Real-time quantitative PCR. Total RNA was extracted from each liver using the 
RNeasy Mini Kit (Qiagen, Tokyo, Japan) as described previously.26  Real-time 
quantitative PCR was performed for TGF-β, α1(I) procollagen (collagen I), plasminogen 
activator inhibitor-1 (PAI-1), carnitine O-palmitoyltransferase-1 (CPT-1), peroxisomal 
proliferator activated receptor-α (PPAR-α), TNF-α, vascular cell adhesion molecule 1 
(VCAM-1) mRNA using the ABI Prism 7900 Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA). The sets of primers and TaqMan probes for 
collagen I were proprietary to Applied Biosystems (TaqMan Gene Expression Assays 
product).  To control for variation in the amount of DNA available for PCR in the 
different samples, gene expression of the target sequence was normalized in relation to 
the expression of an endogenous control, 18S rRNA (TaqMan Control Reagent Kit; 
Applied Biosystems). The PCR conditions were one cycle at 50°C for 2 min, 95°C for 
10 min, followed by 50 cycles at 95°C for 15 s and 58°C for 1 min. 
 
Western blot analysis of 4-HNE-modified proteins.  Livers were homogenized in RIPA 
lysis buffer containing 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% 
NP-40, 0.25% deoxycholic acid, and a protease inhibitor cocktail (Roche Diagnostics, 
Indianapolis, IN).  The following procedures for Western blot analysis have been 
described previously.27
 
Cell culture model and experimental design.  RAW 264.7 macrophages were grown 
in DMEM (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum in a 
humidified 5% CO2 atmosphere at 37°C until they were 90% confluent.  Cells were 
treated with lipopolysaccharide (LPS, Escherichia coli 05:B5, Sigma–Aldrich, St. Louis, 
USA) (1 μg/ml) and tranilast (30 μmol/l, 300μmol/l) for 6 hour.  After treatment, total 
RNA was extracted using the RNeasy Mini Kit (Qiagen, Tokyo, Japan) as described 
previously.26  Gene expression of TNF-α, IL-6 and inducible NO synthase (iNOS) was 
determined by realtime-PCR.  In the next experiment, the cells were treated tranilast 
alone(30 μmol/l, 300 μmol/l) for 6 hour. After treatment, concentration of IL-6 and 
TNF-α in culture medium was determined by ELISA (R&D systems, Minneapolis, USA 
and Bender Medsystems, Vienna, Austria).   
 
 6
   Statistical analysis. All results are shown as means or means ± SEM. Data were 
analyzed by one-way analysis of variance, and P < 0.05 was considered statistically 
significant. All calculations were performed with SPSS version 11.0 software for 
Windows (SPSS Inc., Chicago, IL, USA). 
 
Results 
   Tranilast was well tolerated by rats fed the MCD diet.  Spontaneous-onset type 2 
diabetic OLETF rats were fed with the MCD diet for 8 weeks.  The MCD diet caused 
intense lobular inflammation, and prominent perivenular and pericellular fibrosis in 
zone 3 of the liver (Fig. 1A, B) as previously described.6  To ascertain the most 
effective doses of tranilast, we treated the OLETF-MCD rats with tranilast at three 
concentrations, 1, 1.4, and 2%, which provided an average dose of 160, 190, and 420 
mg kg day , respectively.–1 –1   These are reasonable daily doses for animal experiments, 
as previously determined.22, 28, 29  Tranilast did not affect physical appearance, stool 
composition, coat maintenance, or food or water intake, which indicated that tranilast 
was well tolerated.  Treatment with tranilast dose-dependently ameliorated the liver 
pathology in MCD-OLETF rats (Fig. 1C).  The effects were more prominent in the 2% 
tranilast-treated group, and we thus performed the following investigations in this 
group.  
 
   Metabolic parameters.  Metabolic parameters in OLETF rats and nondiabetic 
control LETO rats fed the MCD diet, with or without 2% tranilast, for 8 weeks are 
shown in Table 1.  Tranilast significantly decreased serum ALT and increased liver 
weight of both OLETF-MCD and LETO-MCD rats.  Blood glucose and triglycerides 
were unaffected by tranilast.  In addition, an insulin loading test showed that 
tranilast-treated rats exhibited no improvement in insulin sensitivity (data not shown).   
 
   Tranilast inhibited activation of stellate cells and development of hepatic fibrosis 
in a dietary animal model of NASH.  Histological analysis with Azan staining 
revealed that treatment with 2% tranilast dramatically prevented the development of 
hepatic fibrosis in LETO-MCD and OLETF-MCD rats (Fig. 2A, B).  Activation of 
hepatic stellate cells is known to play a central role in development of hepatic fibrosis.  
Thus, to examine the effect of tranilast on activation of stellate cells, we performed 
immunohistochemical analysis of α-SMA, a marker for stellate cell activation.  
α-SMA-positive cells significantly increased in the liver of OLETF-MCD rats compared 
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to that in LETO-MCD rats.  Tranilast reduced the numbers of these cells in both 
LETO-MCD and OLETF-MCD rats (Fig. 2C, D).   
 
   Tranilast prevented development of hepatic steatosis.  To date, little has been 
reported on the effect of tranilast on intracellular lipid accumulation.  However, 
unexpectedly, our histological analysis showed that treatment with tranilast clearly 
improved hepatic steatosis in both LETO-MCD and OLETF-MCD rats (Fig. 3A).  
Consistent with the histological findings, tranilast significantly reduced hepatic 
triglyceride content in these two groups of rats (Fig. 3B).   
 
   Tranilast suppressed TGF-β expression in the liver in the dietary animal model of 
NASH.  To clarify the mechanism by which tranilast prevents hepatic fibrosis in rats, 
the expression of TGF-β, a master regulator of fibrogenesis in the liver, was estimated 
by quantitative real-time PCR (Fig. 4A).  Treatment with tranilast down-regulated 
mRNA for TGF-β in the liver of OLETF-MCD rats, and also had a tendency to 
down-regulate it in the liver of LETO-MCD rats.  Moreover, tranilast suppressed the 
expression of TGF-β target genes involved in fibrogenesis, collagen I, and PAI-1 (Fig. 
4B, C).  Consistent with the findings for mRNA, immunohistochemical analysis 
showed suppression of TGF-β protein expression in the liver of tranilast-treated rats 
(Fig. 4D). 
 
   Tranilast up-regulated mRNA expression of genes involved in fatty acid 
β-oxidation.  To clarify the mechanism by which tranilast improves hepatic steatosis in 
the rats, the expression of genes involved in fatty acid β-oxidation was measured by 
quantitative real-time PCR (Fig. 5A, B).  mRNA expression for PPAR-α, a 
transcriptional factor central to the regulation of β-oxidation, was significantly 
up-regulated by tranilast in the liver of OLETF-MCD and LETO-MCD rats.  In 
addition, tranilast also induced mRNA expression for CPT-1, a rate-limiting enzyme for 
β-oxidation that controls fatty acid entry into mitochondria.   
 
Tranilast reduced numbers of Kupffer cells and TNF-α production in a dietary 
animal model of NASH.  To clarify the mechanism by which tranilast improves 
hepatic inflammation in the rats, we evaluated the effect of tranilast on Kupffer cells, 
the resident liver macrophages.  We performed immunohistochemical analysis using a 
monoclonal antibody specific for ED1 antigen, a marker of rat monocytes/macrophages 
and Kupffer cells.  While ED1-positive cells significantly increased in the liver of 
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OLETF-MCD rats compared to that in LETO-MCD rats, tranilast reduced the numbers 
of these cells in both LETO-MCD and OLETF-MCD rats (Fig.6A, B).  As Kupffer 
cells are the primary source of hepatic TNF-α,30 we measured hepatic TNF-α mRNA 
levels.  Real-time PCR analysis showed that tranilast dramatically down-regulated 
mRNA for TNF-α (Fig.6C).  Serum levels of TNF-α were also decreased by treatment 
with tranilast (Table 1).  In addition, tranilast down-regulated mRNA for VCAM-1, the 
adhesion molecules facilitating leucocyte recruitment, in the liver of OLETF-MCD rats, 
and also had a tendency to down-regulate it in the liver of LETO-MCD rats (Fig.6D).
 
Tranilast inhibited LPS-induced TNF-α and IL-6 production in RAW 264.7 
macrophages.  To determine whether tranilast has a direct action on the activated 
macrophages, we performed the experiments by RAW 264.7 cells.  Incubation of 
RAW 264.7 cells with LPS for 6 hours resulted in a remarkable increase of TNF-α, IL-6, 
and iNOS mRNA expression (Fig.7A, B, C).  Concomitant administration of tranilast 
significantly suppressed LPS-induced expresson of these genes.  In addition, the 
release of TNF-α and IL-6 from RAW 264.7 cells into the culture medium was also 
significantly decreased by tranilast treatment (Fig. 7D E).   
 
Tranilast attenuated intrahepatic oxidative stress in the dietary animal model of 
NASH.  To clarify the anti-oxidative effect of tranilast, we estimated 4-HNE-modified 
proteins, a marker of oxidative stress, in the liver lysates by Western blot analysis.  
4-HNE was significantly decreased by tranilast administration in the liver of 
OLETF-MCD and LETO-MCD rats (Fig.8A-D).  In addition, thiobarbituric acid 
reactive substances (TBARS), another marker of oxidative stress, was also estimated by 
western blot analysis.  Hepatic accumulation of TBARS was significantly reduced by 




   Hepatic fibrosis is a well-known histological and biochemical hallmark of NASH.  
Progressive fibrosis causes liver insufficiency and portal hypertension, and is a risk 
factor for developing hepatocellular carcinoma.  Thus, hepatic fibrosis is an important 
therapeutic target for NASH, and various inhibitors of fibrosis are now being 
investigated as potential candidate drugs.31  In the current study, we demonstrated that 
tranilast, an anti-fibrogenic agent, improved hepatic fibrosis in an animal model of 
NASH.  Administration of tranilast inhibited the activation of hepatic stellate cells and 
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reduced expression of genes for TGF-β and its target molecules, which probably led to 
the prevention of fibrosis.  The present study provides in vivo evidence that 
anti-fibrogenic treatment by tranilast is a beneficial and promising treatment approach 
for NASH.   
   Among the numerous pro-fibrogenic mediators, a functional hierarchy might exist, 
which points to TGF-β as being the most effective.32  Concomitant with increased 
activity of TGF-β during hepatic fibrosis, hepatic stellate cells increase the production 
and deposition of collagen.  It is well-known that blockade of TGF-β synthesis or 
signaling using different experimental strategies prevents liver fibrosis in various 
animal models.15–18  To date, however, it is unclear whether an oral inhibitor of TGF-β 
activity is effective in preventing liver fibrosis in animal models.  We demonstrated 
that administration of tranilast reduced TGF-β gene expression and α-SMA-positive 
cells in the liver of MCD-fed rats.  The current data suggest that treatment with 
tranilast ameliorates hepatic fibrosis and liver damage through the direct suppression of 
TGF-β expression.  These findings are supported by a previous in vitro study that 
demonstrated that tranilast inhibits the activation of cultured rat stellate cells through 
the suppression of TGF-β mRNA.10  In addition, tranilast also down-regulated hepatic 
expression of PAI-1, one of the TGF-β target genes.  PAI-1 has been reported to be a 
therapeutic target of metformin for hepatic injury caused by ethanol, 33 which suggests 
that tranilast might also be effective treating in this disease. 
The current study is the first to demonstrate that tranilast exerts broad and profound 
effects on Kupffer cells, the resident liver macrophages.  Previous reports showed that 
tranilast inhibits cytokine release from human monocytes/macrophages,34, 35 however, it 
was unresolved whether tranilast acts upon Kupffer cells.  In liver injury, activated 
Kupffer cells are a major source of inflammatory mediators including cytokines, 
superoxides, nitric oxide, and chemokines.36  Particularly, TNF-α, derived from 
activated Kupffer cells, plays a critical role in the development of various liver diseases 
including nonalcoholic steatohepatitis.37  TNF-α activates Kupffer cells through 
autocrine and paracrine mechanisms,30 and promotes Kupffer cells recruitment by 
enhancing adhesion molecules such as VCAM-1 on endothelial cells, creating a vicious 
cycle.36  Our experiments indicated that TNF-α production in Kupffer 
cells/macrophages are suppressed by tranilast treatment.  Tranilast may attenuate 
MCD-induced hepatic inflammation and accumulation of oxidative stress probably by 
breaking the vicious cycle of Kupffer cells activation and TNF-α production.   
    Obesity, type 2 diabetes, and dyslipidemia frequently coexist with NAFLD.  
Insulin resistance is an underlying factor in these metabolic disorders and may play a 
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critical role in the pathogenesis of NAFLD.  Several lines of evidence have indicated 
that insulin-sensitizing agents, such as pioglitazone, improve histological findings and 
liver injury in both animals and patients with NASH, the progressive form of NAFLD.6, 
38  In the current study, insulin sensitivity in rats was unaffected by treatment with 
tranilast.  In addition, unlike the action of pioglitazone,6, 38 tranilast was beneficial in 
preventing hepatic fibrosis in the LETO-MCD rats, which mimics animal models of 
NASH, without insulin resistance.  These results suggest that the inhibitory action of 
tranilast is mediated through an insulin-resistance-independent pathway.  Therefore, 
nonresponders to insulin-sensitizing agents might benefit from treatment with tranilast 
for preventing hepatic fibrosis in NASH.   
Surprisingly, we found that tranilast prevented the development of not only hepatic 
fibrosis, but also liver steatosis in MCD-induced NASH.  This finding was reinforced 
by the reduction of liver triglyceride content.  In addition, these findings were 
unexpected because little has been reported on the effect of tranilast on intracellular 
lipid accumulation.  Real-time PCR revealed that expression of genes involved in fatty 
acid β-oxidation, such as CPT-I and PPAR-α, were up-regulated, which suggests that 
tranilast-induced enhancement of β-oxidation may have attenuated hepatic steatosis in 
rats.  Our results were consistent with a previous study showing that TGF-β signaling 
pathways suppress PPAR-α activity, a transcriptional factor central to the regulation of 
β-oxidation, and reduce fatty acid β-oxidation in cardiomyocytes.39  Therefore, 
tranilast-mediated inhibition of TGF-β action might enhance β-oxidation through the 
up-regulation of PPAR-α.  However, one limitation of our study is that the analysis 
was performed only at the gene transcriptional levels.  Further studies evaluating the 
alteration of β-oxidation capacity are needed to clarify the mechanism by which 
tranilast attenuates hepatic steatosis.   
In the current study, the OLETF-MCD rats treated with tranilast had a significant body 
weight loss.  Because tranilast significantly reduced body weight in MCD-OLETF rats 
but not in MCD-LETO rats, this action is unlikely due to a toxic effect.  Certainly, we 
cannot rule out the possibility that body weight reduction might, at least in part, 
contribute to the tranilast-induced attenuation of hepatic steatosis and up-regulation of 
gene expression involved in fatty acid β-oxidation.  However, our data indicated the 
direct inhibitory effects of tranilast on activated macrophages both in vivo and in vitro, 
suggesting that tranilast ameliorated the liver pathology independently of its weight 
reducing effects.  The critical parameters contributing to body-weight maintenance 
include caloric intake, physical activity, and adaptive thermogenesis.40, 41  As both 
food intake and physical appearance were unaffected by tranilast, we should examine 
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the effect of tranilast on adaptive thermogenesis and energy expenditure in future.  
Tranilast might inhibit activated macrophages infiltrating into the adipose tissues 
leading to inhibition of adipose tissue hyperplasia.  These unraveled effects of tranilast 
are under investigation in MCD-untreated animal models of obesity and type 2 diabetes 
without cachexia. 
   Serological analysis revealed that all the animals treated with tranilast showed 
improvement of serum ALT levels compared to those without tranilast treatment.  
These findings indicated that treatment with tranilast for 8 weeks did not induce hepatic 
toxicity, as evidenced by the histomorphology of the liver.  Tranilast has long been 
used safely for the treatment of patients with bronchial asthma and atopic dermatitis.  
However, since TGF-β-mediated fibrogenesis is involved in an active wound-healing 
process that is essential for tissue remodeling, long-term treatment with a TGF-β 
inhibitor may produce adverse effects.31  To determine the safety of administering 
tranilast for patients with NASH, further investigations of the long-term outcome are 
needed.   
   In conclusion, our experiments demonstrated that tranilast prevented the 
development of NASH in a dietary rat model, possibly through an 
insulin-resistance-independent pathway.  Our findings suggest that targeting TGF-β 
with tranilast is a novel approach to the prevention and treatment of NASH.   
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Fig. 1.  Tranilast dose-dependently ameliorated liver pathology in OLETF rats fed the 
MCD diet.  Paraffin-embedded sections of the liver were stained with H&E (A) or 
Azan (B) stain (original magnification, ×100).  Histological changes in the liver were 
semiquantitatively expressed as histological scores (C).  The MCD diet caused marked 
macrovesicular steatosis, intense lobular inflammation, and prominent perivenular and 
pericellular fibrosis in zone 3 of the liver of OLETF rats.  Compared to the MCD diet 
alone, the 1.4 and 2% tranilast-mixed diet significantly improved liver steatosis, fibrosis, 
and acinar and portal inflammation (Values are means ± SEM.  *P < 0.05 versus the 
control diet).  
 
Fig. 2.  Tranilast inhibited activation of stellate cells and development of hepatic 
fibrosis.  (A) Paraffin-embedded sections of the liver were stained with Azan stain 
(original magnification, ×100).  (B) Percentages of fibrous area (blue area in Azan 
stain) were calculated under a microscope using an image analysis system. (C) 
Immunohistochemical staining using a monoclonal mouse antihuman α-SMA antibody 
(original magnification, ×100).  (D) The α-SMA-positive area was quantified 
morphometrically in the liver sections.  Compared to the MCD diet alone, the 
tranilast-mixed diet significantly improved liver fibrosis and activation of stellate cells 
(Values are means ± SEM. **P < 0.01 versus the MCD diet). 
 
Fig. 3.  Tranilast prevented development of hepatic steatosis.  (A) Paraffin-embedded 
sections of the liver were stained with H&E (original magnification, ×100).  (B) 
Tranilast significantly reduced hepatic triglyceride content in these two groups of rats 
(Values are means ± SEM. *P < 0.05 versus the MCD diet).  
 
Fig. 4.  Tranilast suppressed hepatic expression of TGF-β.  (A) Treatment with 
tranilast down-regulated mRNA for TGF-β in the liver of OLETF-MCD rats.  (B, C) 
Tranilast suppressed expression of TGF-β target genes, genes for procollagen and PAI-1 
(Values are means ± SEM. *P < 0.05 versus MCD diet; **P < 0.01 versus MCD diet).  
(D)  Paraffin-embedded sections of the liver were immunostained with a TGF-β 
antibody.  Immunohistochemical analysis showed that TGF-β expression was 




Fig. 5.  Tranilast up-regulated the genes involved in fatty acid β-oxidation.  (A) 
mRNA expression for PPAR-α, a transcriptional factor central to the regulation of 
β-oxidation, was significantly up-regulated by tranilast in the liver of OLETF-MCD and 
LETO-MCD rats.  (B) Tranilast induced mRNA expression for CPT-1, a rate-limiting 
enzyme for β-oxidation that controls fatty acid entry into mitochondria (Values are 
means ± SEM. *P < 0.05, **P < 0.01 versus the MCD diet).  
 
Fig. 6.  Tranilast inhibited intrahepatic recruitment of Kupffer cells and TNF-α 
production in a dietary animal model of NASH.  (A) Immunohistochemical staining 
using a ED1 antibody (original magnification, ×100).  (B) The ED1-positive area was 
quantified morphometrically in the liver sections.  Compared to the MCD diet alone, 
the tranilast-mixed diet significantly inhibited the permeation of the macrophage to the 
liver (Values are means ± SEM. **P < 0.01 versus the MCD diet).  (C) Tranilast 
suppressed mRNA expression for TNF-α (Values are means ± SEM. *P < 0.05 versus the 
MCD diet). (D) mRNA expression for VCAM, the adhesion molecules, was 
significantly down-regulated by tranilast in the liver of OLETF-MCD rats.   
 
Fig. 7.  Tranilast inhibited TNF-α, IL-6 and iNOS production in RAW 264.7 
macrophages.  (A) TNF-α mRNA expression was significantly down-regulated by 
tranilast in RAW 264.7 cells stimulated by LPS. (B) IL-6 expression was significantly 
down-regulated by tranilast in RAW cells. (C) iNOS expression was significantly 
down-regulated by tranilast in RAW cells (Values are means ± SEM. *P < 0.05 versus 
LPS(+), tranilast(-)). (D) The concentration of TNF-α in medium was decreased by 
treatment of tranilast  (E) The concentration of IL-6 in medium was decreased by 
treatment of tranilast (Values are means ± SEM. *P < 0.05, **P < 0.01 versus 
tranilast(-)). 
 
Fig. 8.  Tranilast suppressed oxidative stress.  Western blot analysis of 
4-HNE-modified proteins (A), (C), and these quantification (B), (D), showed that 
tranilast significantly decreased 4-HNE in the liver of OLETF-MCD and LETO-MCD 











Table 1. Effects of MCD and MCD+tranilast diet on metabolic parameters at 8 weeks of treatment
 OLETF   LETO   
Treatment (－) Tranilast (2%) (－) Tranilast (2%)
Body weight (g) 402 ± 5.4 359 ± 4.5* 384 ± 4.6+ 366 ± 6.7 
Food intake (kcal/day) 31.1 ± 2.9 36.5 ± 7.1 43.7 ± 1.7+ 41.6 ± 0.8+ 
Tranilast intake (mg/kg BW/day)  (–) 423 ± 99 (–) 482 ± 21 
Liver weight (g) 14.2 ± 0.3 15.8 ± 0.5* 9.9 ± 0.4+ 12.6 ± 0.2*+
Serum glucose (fasting) (mg/dL) 107 ± 7.1 138 ± 5.0 118 ± 9.6 122 ± 4.1+ 
60 min (mg/dL) 222 ± 24.3 238 ± 30.0 172 ± 8.6 150 ± 5.6 
120 min (mg/dL) 166 ± 16.9 246 ± 43.8 141 ± 6.0 144 ± 8.2+ 
Plasma ALT levels (U/L) 165 ± 22.1 80.8 ± 9.9* 118.4 ± 11.0 59.2 ± 3.2* 
Serum TNF-α levels (pg/ml) 4.0 ± 3.0 unmeasurable 0.8 ± 0.7 unmeasurable
Data are means ± SEM (n = 9–11).     


























































































































Tranilast (-)  (+)




















































































Tranilast (-)  (+)



















































































































































OLETF                       LETO
Tranilast (-)  (+) (-)  (+) Tranilast (-)  (+) (-)  (+)




















































OLETF                    LETO
Tranilast (-)  (+) (-)  (+) Tranilast (-)  (+) (-)  (+)
**
B
OLETF                     
LETO
Tranilast (-)  (+)
A
OLETF                    LETO































































































































































































































































































































Tranilast (-)  (+)
DC
